Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
SAN ANTONIO - Wytec International (OTCQB:WYTC) will host a Public Safety/Investor Seminar on September 2, 2025, at the Intercontinental Riverwalk Hotel in San Antonio to demonstrate its gunshot detection and drug sensing technology, according to a company press release. The company’s stock, currently trading at $1.00, has shown strong momentum with a 35% gain year-to-date, though it remains 76% below its 52-week high of $4.25.
With an InvestingPro Financial Health Score of 1.16 (labeled as "WEAK"), the telecommunications company announced a $10 million secured note offering with a 9.5% return, available only to accredited investors under SEC Rule 506(c). Part of the proceeds will fund a multi-government sales program through telecom master channel agents. The company’s current ratio of 0.12 and negative return on assets suggest careful financial management will be crucial.
The seminar will follow Wytec’s May 20 completion of a live gunshot detection pilot project at the Sons of Liberty Gun Range in San Antonio. The company has reserved 50 of the 100 available seats for members of TXShare, a cooperative purchasing program representing 170 U.S. cities, 50 counties, and over 40 special districts including transit authorities and police departments. Want deeper insights? InvestingPro subscribers get access to 12 additional ProTips and comprehensive financial metrics for WYTC.
Wytec plans to offer TXShare Cooperative members a 30-day no-cost trial of its AI-integrated gunshot and drug detection solution. The company has a Master Service Agreement with the North Central Texas Council of Governments resulting from a TXShare request for proposal.
The remaining seminar seats are allocated for top shareholders and potential new investors from family offices and institutions.
Wytec, which holds patents for its AI gunshot technology approved by the U.S. Patent and Trademark Office, aims to uplist from the OTCQB Market to a major exchange by the end of 2025. According to InvestingPro analysis, the stock appears overvalued at current levels, with revenue declining 52% in the last twelve months and an EBITDA of -$2.26 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.